Simon et al. defined an active tumor microenvironment as having an accumulation of CD8+PD-1+ activated effector T cells, indicating a sub-population of about 38% of cancer patients that are able to respond to anti-PD-1 therapy [106]. This evidence concerns the gene CD8A and neoplasm.